Search Results - pharmaceuticals




7 Results Sort By:
Drugs that disrupt interactions between ELK1 and the androgen receptor to suppress growth of both early stage and castration resistant prostate cancer
Background:Prostate cancer is the second-most commonly diagnosed cancer among men and the fifth most common cause of male cancer death worldwide. Although tumors are often initially sensitive to medical or surgical therapies that decrease levels of testosterone, continued disease progression generally represents a transition to the lethal variant. In...
Published: 10/22/2019   |   Inventor(s): Manohar Ratnam, Rayna Rosati, Mugdha Patki
Keywords(s):  
Category(s): Life Science, Therapeutics, Oncology, Drug Discovery, Pharmaceuticals
Long non-protein-coding RNA molecules as therapeutics for epilepsy.
Long Non-Coding RNA Molecules as Therapeutics for Epilepsy WSU Tech#: 12-1089 Technology Summary: Long Non-coding RNA (lncRNA) were first described in 2002 from mouse, making this a relatively new technology. lncRNA transcripts far exceed the number of protein coding mRNAs in the mammalian transcriptome, but in lower copy numbers. Inventors have...
Published: 5/19/2017   |   Inventor(s): Jeffrey Loeb, Leonard Lipovich
Keywords(s):  
Category(s): Medical, Bioinformatics, Biomedical, Biotechnology, Diagnostic, Diagnostics, Drug Discovery, Pharmaceuticals, Therapeutics
CARP-1/CCAR1 Functional Mimetics (CFMs): Novel small molecule suppressors of human breast cancer cell growth.
BackgroundCARP-1 (Cell cycle and apoptosis regulator protein) is a regulator of cell growth signaling. CARP-1 plays an important role in apoptosis (cell death) induction in human breast cancer (HBC) cells in the presence of the chemotherapy agent Adriamycin. The researchers have found that CARP-1 inhibits cell growth by binding with the anaphase...
Published: 5/19/2017   |   Inventor(s): Arun Rishi
Keywords(s):  
Category(s): Medical, Drug Discovery, Life Science, Oncology, Pharmaceuticals
Topical IL-1Ra (anakinra) in the form of gel to treat persistent diabetic skin and corneal wounds
BackgroundAnakinra (aka. Kineret) is a recombinant human IL-1Ra that was developed by Amgen. It is currently used to treat moderately to severely active rheumatoid arthritis, but also treats neonatal-onset multisystem inflammatory disease (NOMID). Anakinra is given as an IV dose and the drug is no longer under patent. The properties of Anakinra are...
Published: 5/25/2016   |   Inventor(s): Fu-Shin Yu
Keywords(s):  
Category(s): Biologicals, Drug Discovery, Pharmaceuticals, Therapeutics
Co-polymer Stabilizers for Pressured Metered Dose Inhalers (pMDIs)
A series of novel co polymer surfactants with the general structure LAmEOnLAm were developed along with a Colloidal Probe Microscopy (CPM) method to optimize the surfactant composition using adhesion forces to improve stabilization of drug dispersions. This expands the range of biomolecules and micronized drug particles that can be formulated with pMDIs....
Published: 8/14/2013   |   Inventor(s): Sandro Da Rocha, Libo Wu
Keywords(s): Assay, Asthma, Compound, Device, Drug Delivery, Formulation, Instrumentation, Method, Pharmaceuticals, Process, Therapeutics
Category(s): Chemicals, Drug Delivery, Pharmaceuticals, Instrumentation, Materials
Peptide Antimicrobial
In vivo Display Technology for the Isolation of Antimicrobial Peptides Professor Philip R. Cunningham, Ph.D. Department of Biological Sciences @ Wayne State University Interest in peptides as antimicrobial agents has increased dramatically in recent years, driven primarily by the development of new technologies for producing, screening and analyzing...
Published: 5/3/2011   |   Inventor(s): Philip Cunningham, Wes Colangelo
Keywords(s):  
Category(s): Pharmaceuticals, Life Science, Research tools, Assays, Biological materials, Protein/peptides
Functional Improvements in Fahr Disease
Detailed Description Idiopathic cerebral calcification (a.k.a. Brain Stones) can be associated with a progressive neurological disorder for which there is no known treatment. This invention is a repurposing of an existing FDA approved compound for a new use. It relates to the treatment of Fahr?s Disease by the administration of a class of drugs...
Published: 5/18/2010   |   Inventor(s): Jeffrey Loeb
Keywords(s):  
Category(s): Pharmaceuticals